Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GlaxoSmithKline 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GlaxoSmithKline 2Q

Pharmaceutical sales were $8.7 billion in the quarter (-11%). Seretide/Advair sales were flat at $1.9 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 2Q

2Q Revenues: $10.5 billion (-10%)

2Q Earnings: $2.3 billion (-12%)

YTD Revenues: $20.3 billion (-12%)

YTD Earnings: $3.9 billion (-25%)

Comments: Pharmaceutical sales were $8.7 billion in the quarter (-11%). Seretide/Advair sales were flat at $1.9 billion. Valtrex sales were $590 million (+7%). Combivir sales were down 23% to $160 million. Epzicom/Kivexa sales were $202 million (-2%). Seroxat/Paxil sales were $215 million (-15%). Avodart sales were up 14% to $208 million. Avandia product sales were $309 million (-20%). Augmentin sales were $230 million (-11%). Vaccine revenues in the quarter were up 9% to $1.2 billion, with Rotarix sales up 59% to $110 million and Cervarix sales of $113 million, up from $30 million in 2Q08. R&D expenses were down 6% to $1.5 billion.

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters